文献速递炎症性肠病

炎症性肠病治疗药物对COVID-19结局的影响:一项国际注册研究结果

Effect of IBD medications on COVID-19 outcomes: results from an international registry.
PubMed 文献 · Gut · 2020-10-20

该国际注册研究纳入47个国家1439例确诊COVID-19的炎症性肠病患者,评估不同药物类别与重症COVID-19的关联。相比TNF拮抗剂单药治疗,硫嘌呤单药(aOR 4.08)及TNF拮抗剂联合硫嘌呤(aOR 4.01)与重症风险升高相关;氨基水杨酸类/柳氮磺吡啶使用与重症风险升高相关(aOR 1.70)。作者认为联合治疗和硫嘌呤可能与重症风险升高相关,生物制剂类别间未见显著差异。

要点

  • 相比TNF拮抗剂单药,硫嘌呤单药(aOR 4.08,95%CI 1.73–9.61)与重症COVID-19风险升高相关。
  • TNF拮抗剂联合硫嘌呤与重症风险升高相关(aOR 4.01,95%CI 1.65–9.78)。
  • 任何氨基水杨酸类/柳氮磺吡啶使用与重症风险升高相关(aOR 1.70,95%CI 1.26–2.29)。

核心结论

  • 联合治疗和硫嘌呤可能与重症COVID-19风险升高相关。
  • 生物制剂类别之间比较未观察到显著差异。
  • 作者认为这些发现需在大型人群队列中确认。

研究设计与样本

  • SECURE-IBD为大型国际注册研究,用于监测确诊COVID-19的IBD患者结局。
  • 纳入47个国家1439例病例(平均年龄44.1岁,51.4%为男性)。
  • 采用多变量回归与广义估计方程,以国家为随机效应。
  • 重症COVID-19定义为入住ICU、使用呼吸机和/或死亡。

主要发现

  • 1439例中112例(7.8%)发生重症COVID-19。
  • 相比TNF拮抗剂单药,硫嘌呤单药与重症风险升高相关(aOR 4.08,95%CI 1.73–9.61)。
  • 相比TNF拮抗剂单药,TNF拮抗剂联合硫嘌呤与重症风险升高相关(aOR 4.01,95%CI 1.65–9.78)。
  • 任何氨基水杨酸类/柳氮磺吡啶使用相比未使用与重症风险升高相关(aOR 1.70,95%CI 1.26–2.29);以TNF拮抗剂单药为参照时该风险估计升高(aOR 3.52,95%CI 1.93–6.45)。
  • 白介素-12/23拮抗剂(aOR 0.98,95%CI 0.12–8.06)和整合素拮抗剂(aOR 2.42,95%CI 0.59–9.96)与TNF拮抗剂单药相比风险无显著差异。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者认为联合治疗和硫嘌呤可能与重症COVID-19风险升高相关,该发现需在大型人群队列中确认。

局限性

  • 作者认为这些发现需在大型人群队列中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We sought to evaluate COVID-19 clinical course in patients with IBD treated with different medication classes and combinations. DESIGN: Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We used multivariable regression with a generalised estimating equation accounting for country as a random effect to analyse the association of different medication classes with severe COVID-19, defined as intensive care unit admission, ventilator use and/or death. RESULTS: 1439 cases from 47 countries were included (mean age 44.1 years, 51.4% men) of whom 112 patients (7.8%) had severe COVID-19. Compared with tumour necrosis factor (TNF) antagonist monotherapy, thiopurine monotherapy (adjusted OR (aOR) 4.08, 95% CI 1.73 to 9.61) and combination therapy with TNF antagonist and thiopurine (aOR 4.01, 95% CI 1.65 to 9.78) were associated with an increased risk of severe COVID-19. Any mesalamine/sulfasalazine compared with no mesalamine/sulfasalazine use was associated with an increased risk (aOR 1.70, 95% CI 1.26 to 2.29). This risk estimate increased when using TNF antagonist monotherapy as a reference group (aOR 3.52, 95% CI 1.93 to 6.45). Interleukin-12/23 and integrin antagonists were not associated with significantly different risk than TNF antagonist monotherapy (aOR 0.98, 95% CI 0.12 to 8.06 and aOR 2.42, 95% CI 0.59 to 9.96, respectively). CONCLUSION: Combination therapy and thiopurines may be associated with an increased risk of severe COVID-19. No significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.MKH should be changed to MDK for co-last author line.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2020. PMID: 33082265. doi:10.1136/gutjnl-2020-322539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。